CPFP
CTXR icon

Clear Perspectives Financial Planning’s Citius Pharmaceuticals CTXR Stock Holding History

Clear Perspectives Financial Planning’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$468 Hold
16
– – ﹤0.01% 183
2022
Q4 		$316 Buy
+16
New +$437 ﹤0.01% 213
2022
Q2 		– Sell
-16
Closed -$1K – 212
2022
Q1 		$1K Hold
16
– – ﹤0.01% 207
2021
Q4 		$1K Buy
+16
New +$726 ﹤0.01% 216

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Clear Perspectives Financial Planning's CTXR Position: Q1 2023 in Review

Clear Perspectives Financial Planning held its Citius Pharmaceuticals (CTXR) position steady in Q1 2023 at 16 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #183.

Clear Perspectives Financial Planning first reported a position in CTXR in Q4 2021 and has held it in 4 quarters since. The position peaked at $1K in Q1 2022. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

  • Clear Perspectives Financial Planning held 16 shares of Citius Pharmaceuticals worth $468 as of Q1 2023.
  • Clear Perspectives Financial Planning left its Citius Pharmaceuticals share count unchanged in Q1 2023.
  • Citius Pharmaceuticals made up ﹤0.01% of Clear Perspectives Financial Planning's portfolio in Q1 2023, its #183 holding.
  • Clear Perspectives Financial Planning first reported a position in Citius Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • Clear Perspectives Financial Planning's Citius Pharmaceuticals position peaked at $1K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on Clear Perspectives Financial Planning's 13F filing for Q1 2023, filed 11 May 2023.